Systemic sclerosis is characterized by widespread fibrosis of the skin and internal organs, vascular impairment, and dysregulation of innate and adaptive immune system. Growing evidence indicates that T-cell proliferation and cytokine secretion play a major role in the initiation of systemic sclerosis, but the role of T helper 17 cells and of interleukin-17 cytokines in the development and progression of the disease remains controversial. In particular, an equally distributed body of literature supports both pro-fibrotic and anti-fibrotic effects of interleukin-17, suggesting a complex and nuanced role of this cytokine in systemic sclerosis pathogenesis that may vary depending on disease stage, target cells in affected organs, and inflammatory milieu. Although interleukin-17 already represents an established therapeutic target for several immune-mediated inflammatory diseases, more robust experimental evidence is required to clarify whether it may become an attractive therapeutic target for systemic sclerosis as well.
MeierFMFrommerKWDinserR, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis2012; 71(8): 1355–1360.
2.
VargaJTrojanowskaMKuwanaM.Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord2017; 2(3): 137–152.
3.
ScherJUAbramsonSB.The microbiome and rheumatoid arthritis. Nat Rev Rheumatol2011; 7: 569–578.
4.
BarautJMichelLVerrecchiaF, et al. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev2010; 10(2): 65–73.
5.
SakkasLIPlatsoucasCD.Is systemic sclerosis an antigen-driven T cell disease?Arthritis Rheum2004; 50(6): 1721–1733.
6.
GiovannettiARosatoERenziC, et al. Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol2010; 137(1): 122–133.
7.
HarringtonLEHattonRDManganPR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol2005; 6(11): 1123–1132.
8.
ParkHLiZYangXO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol2005; 6(11): 1133–1141.
9.
RadstakeTRvan BonLBroenJ, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS ONE2009; 4: e5903.
10.
Rodríguez-ReynaTSFuruzawa-CarballedaJCabiedesJ, et al. Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int2012; 32(9): 2653–2660.
11.
TruchetetMEBrembillaNCMontanariE, et al. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther2011; 13(5): R166.
12.
OmenettiSBussiCMetidjiA, et al. The intestine harbors functionally distinct homeostatic tissue-resident and inflammatory Th17 cells. Immunity2019; 51: 77.e6–89.e6.
13.
MiossecPKollsJK.Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov2012; 11(10): 763–776.
14.
TabarkiewiczJPogodaKKarczmarczykA, et al. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp2015; 63(6): 435–449.
VeldhoenM.Interleukin 17 is a chief orchestrator of immunity. Nat Immunol2017; 18: 612–621.
17.
MoninLGaffenSL.Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol2018; 10: a028522.
18.
BreviACogrossiLLGraziaG, et al. Much more than IL-17A: cytokines of the IL-17 family between microbiota and cancer. Front Immunol2020; 11: 565470.
19.
CuaDJTatoCM.Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol2010; 10(7): 479–489.
20.
McGeachyMJCuaDJGaffenSL.The IL-17 family of cytokines in health and disease. Immunity2019; 50: 892–906.
21.
GaffenSLJainRGargAV, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol2014; 14(9): 585–600.
22.
ManganPRSuLJJennyV, et al. Dual inhibition of interleukin-23 and interleukin-17 offers superior efficacy in mouse models of autoimmunity. J Pharmacol Exp Ther2015; 354(2): 152–165.
23.
PatelDDKuchrooVK.Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity2015; 43: 1040–1051.
24.
ChizzoliniCDufourAMBrembillaNC.Is there a role for IL-17 in the pathogenesis of systemic sclerosis?Immunol Lett2018; 195: 61–67.
25.
XingXYangJYangX, et al. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS ONE2013; 8(12): e85032.
26.
FossiezFDjossouOChomaratP, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med1996; 183: 2593–2603.
27.
KurasawaKHiroseKSanoH, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum2000; 43(11): 2455–2463.
28.
GuLXuQCaoH.1,25(OH)2D3 protects liver fibrosis through decreasing the generation of TH17 cells. Med Sci Monit2017; 23: 2049–2058.
29.
WreeAMcGeoughMDInzaugaratME, et al. NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice. Hepatology2018; 67(2): 736–749.
30.
Zepeda-MoralesASDel Toro-ArreolaSGarcía-BenavidesL, et al. Liver fibrosis in bile duct-ligated rats correlates with increased hepatic IL-17 and TGF-β2 expression. Ann Hepatol2016; 15(3): 418–426.
31.
MengFWangKAoyamaT, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology2012; 143(3): 765.e3–776.e3.
32.
AmaraSLopezKBananB, et al. Synergistic effect of pro-inflammatory TNFα and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosis. Mol Immunol2015; 64(1): 26–35.
33.
TanZQianXJiangR, et al. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol2013; 191: 1835–1844.
34.
ChakirJShannonJMoletS, et al. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol2003; 111(6): 1293–1298.
35.
JiangGLiuCTZhangWD.IL-17A and GDF15 are able to induce epithelial-mesenchymal transition of lung epithelial cells in response to cigarette smoke. Exp Ther Med2018; 16(1): 12–20.
36.
WilsonMSMadalaSKRamalingamTR, et al. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med2010; 207: 535–552.
37.
ZhouXLoomis-KingHGurczynskiSJ, et al. Bone marrow transplantation alters lung antigen-presenting cells to promote TH17 response and the development of pneumonitis and fibrosis following gammaherpesvirus infection. Mucosal Immunol2016; 9(3): 610–620.
38.
FengWLiWLiuW, et al. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol2009; 87(3): 212–218.
39.
LiuWWangXFengW, et al. Lentivirus mediated IL-17R blockade improves diastolic cardiac function in spontaneously hypertensive rats. Exp Mol Pathol2011; 91(1): 362–367.
40.
ValenteAJYoshidaTGardnerJD, et al. Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1. Cell Signal2012; 24(2): 560–568.
41.
LiuYZhuHSuZ, et al. IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCβ/Erk1/2/NF-κB-dependent signaling pathway. Int Immunol2012; 24(10): 605–612.
42.
ZhouSFYuanJLiaoMY, et al. IL-17A promotes ventricular remodeling after myocardial infarction. J Mol Med2014; 92(10): 1105–1116.
43.
ChangSLHsiaoYWTsaiYN, et al. Interleukin-17 enhances cardiac ventricular remodeling via activating MAPK pathway in ischemic heart failure. J Mol Cell Cardiol2018; 122: 69–79.
44.
FaustSMLuGMariniBL, et al. Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. J Immunol2009; 183: 7297–7306.
45.
NeedlemanBWWigleyFMStairRW.Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum1992; 35(1): 67–72.
46.
ScalaEPallottaSFrezzoliniA, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol2004; 138(3): 540–546.
47.
KochAEKronfeld-HarringtonLBSzekaneczZ, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology1993; 61(5–6): 239–246.
48.
YangXYangJXingX, et al. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther2014; 16: R4.
49.
ZhouYHouWXuK, et al. The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis. Hum Immunol2015; 76(1): 22–29.
50.
ValentiniGDella RossaABombardieriS, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis2001; 60: 592–598.
51.
LiuMYangJXingX, et al. Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway. Arthritis Res Ther2014; 16: 4223.
52.
TruchetetMEBrembillaNCMontanariE, et al. Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum2013; 65(5): 1347–1356.
53.
LonatiPABrembillaNCMontanariE, et al. High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis. PLoS ONE2014; 9(8): e105008.
54.
KornTBettelliEOukkaM, et al. IL-17 and Th17 cells. Annu Rev Immunol2009; 27: 485–517.
55.
OguraHMurakamiMOkuyamaY, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity2008; 29: 628–636.
56.
KoendersMIKollsJKOppers-WalgreenB, et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum2005; 52(10): 3239–3247.
57.
SimonianPLRoarkCLWehrmannF, et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol2009; 182: 657–665.
58.
ParkMJMoonSJLeeEJ, et al. IL-1-IL-17 signaling axis contributes to fibrosis and inflammation in two different murine models of systemic sclerosis. Front Immunol2018; 9: 1611.
59.
LeiLZhongXNHeZY, et al. IL-21 induction of CD4+ T cell differentiation into Th17 cells contributes to bleomycin-induced fibrosis in mice. Cell Biol Int2015; 39(4): 388–399.
60.
FrançoisAGombaultAVilleretB, et al. B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. J Autoimmun2015; 56: 1–11.
61.
MiSLiZYangHZ, et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol2011; 187: 3003–3014.
62.
OkamotoYHasegawaMMatsushitaT, et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum2012; 64(11): 3726–3735.
63.
HsuHCYangPWangJ, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol2008; 9(2): 166–175.
64.
BergerMSteenVD.Role of anti-receptor autoantibodies in pathophysiology of scleroderma. Autoimmun Rev2017; 16(10): 1029–1035.
65.
NakashimaTJinninMYamaneK, et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol2012; 188: 3573–3583.
66.
MurataMFujimotoMMatsushitaT, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?J Dermatol Sci2008; 50(3): 240–242.
67.
LewisBPBurgeCBBartelDP.Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell2005; 120: 15–20.
68.
AgarwalSMisraRAggarwalA.Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol2008; 35(3): 515–519.
69.
WeiJBhattacharyyaSTourtellotteWG, et al. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev2011; 10(5): 267–275.
70.
BrembillaNCMontanariETruchetetME, et al. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther2013; 15: R151.
71.
BoukampPBreitkreutzDStarkHJ, et al. Mesenchyme-mediated and endogenous regulation of growth and differentiation of human skin keratinocytes derived from different body sites. Differentiation1990; 44(2): 150–161.
72.
DufourAMBorowczyk-MichalowskaJAlvarezM, et al. IL-17A dissociates inflammation from fibrogenesis in systemic sclerosis. J Invest Dermatol2020; 140(1): 103.e8–112.e8.
73.
GonçalvesRSGPereiraMCDantasAT, et al. IL-17 and related cytokines involved in systemic sclerosis: perspectives. Autoimmunity2018; 51(1): 1–9.
74.
ZengCKahlenbergJMGudjonssonJE.IL-17A softens the skin: antifibrotic properties of IL-17A in systemic sclerosis. J Invest Dermatol2020; 140(1): 13–14.
75.
LeonardiCL.Antibodies in the treatment of psoriasis: IL-12/23 p40 and IL-17a. Semin Cutan Med Surg2016; 35: S74–S77.
76.
LebwohlMLeonardiCGriffithsCE, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol2012; 66(5): 731–741.
77.
KavanaughARitchlinCRahmanP, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis2014; 73(6): 1000–1006.
78.
MenterACatherJCJarrattM, et al. Efficacy of secukinumab on moderate-to-severe plaque psoriasis affecting different body regions: a pooled analysis of four phase 3 studies. Dermatol Ther2016; 6(4): 639–647.
79.
AlzabinSAbrahamSMTaherTE, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis2012; 71(10): 1741–1748.
80.
Queiroz-JuniorCMBessoniRLCCostaVV, et al. Preventive and therapeutic anti-TNF-α therapy with pentoxifylline decreases arthritis and the associated periodontal co-morbidity in mice. Life Sci2013; 93: 423–428.
81.
XueyiLLinaCZhenbiaoW, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy. J Clin Immunol2013; 33(1): 151–161.
82.
McGovernJLNguyenDXNotleyCA, et al. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum2012; 64(10): 3129–3138.
83.
YueCYouXZhaoL, et al. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int2010; 30(12): 1553–1557.
84.
Van de VeerdonkFLLauwerysBMarijnissenRJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum2011; 63(6): 1507–1516.
85.
LaiKZengKZengF, et al. Allogeneic adipose-derived stem cells suppress Th17 lymphocytes in patients with active lupus in vitro. Acta Biochim Biophys Sin2011; 43(10): 805–812.
86.
LiYJiangLZhangS, et al. Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. Rheumatol Int2012; 32(8): 2415–2422.
87.
TruchetetMEAllanoreYMontanariE, et al. Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis. Ann Rheum Dis2012; 71(12): 2044–2050.
88.
RoofehDLinCJFGoldinJ, et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol2021; 73(7): 1301–1310.
89.
KhannaDLinCJFFurstDE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med2020; 8(10): 963–974.
90.
ZacayGLevyY.Outcomes of patients with systemic sclerosis treated with tocilizumab: case series and review of the literature. Best Pract Res Clin Rheumatol2018; 32(4): 563–571.
91.
HuangYFanYLiuY, et al. Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials. Clin Rheumatol2019; 38(10): 2765–2776.
92.
MeasePJHelliwellPSHjulerKF, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis2021; 80(2): 185–193.
93.
MadureiraPPimentaSSBernardoA, et al. Off-label use of tocilizumab in psoriatic arthritis: case series and review of the literature. Acta Reumatol Port2016; 41(3): 251–255.
94.
LebwohlMStroberBMenterA, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med2015; 373(14): 1318–1328.
95.
PappKAReichKPaulC, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol2016; 175(2): 273–286.
96.
MarighelaTFArismendiMIMarvulleV, et al. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial. Rheumatology2019; 58: 1985–1990.
